Altimmune: Positive Topline Results from 24-Week Trial in Non-Alcoholic Fatty Liver Disease

 

• Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeks
• Significant reductions in serum alanine aminotransferase (ALT) and corrected T1 (cT1) observed, both established markers of liver inflammation
• Mean weight loss of 7.2% (placebo adjusted 6.0%) in subjects without diabetes at the 1.8 mg dose
• Glycemic control maintained with trends toward improvements in fasting glucose and HbA1c in subjects with diabetes
• Meaningful reductions in blood pressure with minimal increases in heart rate
• Altimmune to host conference call today at 8:30 am ET  

Altimmune management will host a conference call and webcast with a slide presentation presented by Dr. Stephen A. Harrison beginning at 8:30 am E.T. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Conference Call Information:
Date:	Tuesday, December 20
Time:	8:30 am Eastern Time
Webcast:	To listen, the conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Dial-in:	To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call. https://www.biospace.com/article/releases/altimmune-announces-positive-topline-results-from-24-week-12-week-extension-trial-of-pemvidutide-in-subjects-with-non-alcoholic-fatty-liver-disease-nafld-/